Company intelligence / Profile preview
UWELL Biopharma
New Taipei City, Taiwanpmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
UWELL Biopharma has advanced a portfolio of autologous CAR-T therapies targeting hematological tumors. Its lead candidate UWC19 targets CD19-positive hematologic malignancies and has reached Phase II for lymphoblastic lymphoma. Preclinical data show effective elimination of CD19-positive tumor cells with a favorable toxicity profile. The company also developed NKG2D-targeted CAR-T therapies that have shown robust antitumor efficacy in xenograft models but were discontinued in clinical development for glioblastoma.
- Therapeutic areas
- HematologyOncology
- Modalities
- Autologous CAR-T cell therapyCAR-NK cell therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations with clinical teams and partners in Taiwan, China, Malaysia
Beyond the preview
Go deeper on UWELL Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UWELL Biopharma.